SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences, a late-stage clinical biopharmaceutical company, is advancing a focused oncology pipeline in WT1-directed immunotherapy and CDK9 inhibition for hematologic malignancies and solid tumors. Its lead candidate, galinpepimut-S (GPS), licensed from Memorial Sloan Kettering, is in Phase 3 for acute myeloid leukemia. SELLAS is also advancing SLS009 (tambiciclib), a differentiated, potentially first- and best-in-class CDK9 inhibitor in Phase 2. Visit www.sellaslifesciences.com.